Epilepsy, history of CNS disorder; G6PD deficiency, or myasthenia gravis. Maintain adequate fluid intake to avoid the risk of crystalluria. Discontinue if if patients experience tendon pain, inflammation or rupture. Avoid exposure to strong sunlight or sunlamps. Patients w/ QT prolongation or relevant risk factors eg, uncorrected electrolyte disturbances, bradycardia, or preexisting cardiac disease. MRSA infections. Renal impairment. Pregnancy & lactation. Patients <18 yr.
May increase plasma conc of drugs that are metabolised by CYP450 isoenzyme eg, theophylline & tizanidine. Enhances the effect of oral anticoagulants eg, warfarin & glibenclamide. Increased plasma conc w/ probenecid. May alter serum conc of phenytoin. Potential to prolong the QT interval of class Ia antiarrhythmic drugs (eg, quinidine & procainamide) or class III antiarrhythmics (eg, amiodarone & sotalol). Caution when used w/ drugs known to prolong the QT interval (eg, astemizole & terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs).
Sign Out
